# Market Mayhem: A Reverse-Split Rollercoaster!

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-08-29T14:00:00.254Z
Source: https://newsyai.com/edition/77726340-1004-458e-ad49-05bffbf71c88
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

**Market Mayhem: Reverse-Split Circus 11.0 – AI Agents, Bio Bombs & Glucose Goblins (August 29, 2026 Edition!)**

Futures mixed (Dow flatter than a banker’s apology, Nasdaq still chasing AI/chip dreams like a dog with a laser pointer, crude oil doing its usual volatility striptease). MVLS $5M drama on pause, but the microcap reverse-split parade marches on like it’s auditioning for delisting hell. Yesterday’s cyber stiffies, fintech fumbles, and wellness wedgies? Yesterday’s news. Fresh meat today: an agentic AI rebrand play at 1-for-20 (effective yesterday, split-adjusted trading Monday), a radiation-bio outfit at 1-for-25 (effective Monday), and a glucose-monitoring/biopharma hybrid at 1-for-15 (effective Monday). Bulls chant “tiny float = rocket fuel”; bears smell serial dilution, cash bonfires, and governance graves.[[1]](https://www.globenewswire.com/news-release/2026/08/27/3352004/0/en/change-agents-announces-1-for-20-reverse-stock-split.html?pdf=1)[[1]](https://www.globenewswire.com/news-release/2026/08/27/3352004/0/en/change-agents-announces-1-for-20-reverse-stock-split.html?pdf=1)

### 1) CHGA (Change Agents Corp.): “1-for-20 Agentic AI Stiffy vs. Counter-Drone Hype & Nasdaq Bid-Price Squeeze”

**Why it’s loud**  
1-for-20 reverse split effective August 28, 2026 (close), with split-adjusted trading on Nasdaq starting August 31. Formerly Avalon GloboCare (rebranded July 2026), now pushing agentic AI software solutions plus counter-UAS/drone defense plays (Seagate partner program, IDGA membership, Major General on advisory board). Post-split float shrinks to ~930k shares. Multiple prior splits and recent ELOC filings scream dilution potential.[[2]](https://ir.changeagentscorp.com/)[[3]](https://finance.yahoo.com/markets/stocks/articles/change-agents-announces-1-20-123000610.html)

**Bull case (compliance rocket + AI boner)**  
20x ratio + “agentic AI + autonomous defense tailwinds” = $2–6+ rip on the microscopic float. Ride the drone/AI wave, degens—shrunken float = insane percentage moves on any contract win or partnership news!

**Bear case (dilution gangbang & rebrand limp dick)**  
Aggressive ratio on a serial-split, name-changing player with ELOCs and governance questions screams pure desperation; equity raises = sub-penny graveyard after the pop. Short the fade before the next treasury dump!

**My take, first principles (real AI signal vs. listing cancer)**  
Genuine pivot into hot AI/counter-drone narratives could spark short-term momentum on news flow, but repeated compliance drama, tiny float volatility, and microcap dilution risks scream high-risk lottery ticket. Narrative lottery with moonshot odds but graveyard probability. Scalp the spunk? **$0.08–2.20** range, **$0.40C** AI pump—**P$0.08** dilution fade.

### 2) VBIO (Valion Bio, Inc.): “1-for-25 Bio Stiffy vs. Radiation Drug Pipeline & Nasdaq Compliance Desperation”

**Why it’s loud**  
1-for-25 reverse split effective August 31, 2026 (12:01 a.m. ET), with split-adjusted trading same day on Nasdaq. Biotech focused on entolimod (radiation GI injury, Ukraine Ministry review, U.S. gov-funded studies). Recent CEO ouster, Series B financing/royalty deals, and massive compliance pressure (deadline September 15). Tiny market cap and prior dilution flags.[[4]](https://www.sec.gov/Archives/edgar/data/1787740/000168316826006742/valion_ex9901.htm)[[5]](https://www.stocktitan.net/sec-filings/VBIO/8-k-valion-bio-inc-reports-material-event-5c36aee30c5b.html)

**Bull case (compliance rocket + bio boner)**  
25x ratio + “radiation countermeasures + Ukraine/gov pipeline hype” = $1–4+ rip on the shrunken float. Ride the defense/biotech wave, apes—tiny float = massive percentage moves on any regulatory or funding update!

**Bear case (dilution tsunami & execution limp dick)**  
Extreme ratio on a player with cash burn, leadership turnover, and serial compliance issues screams pure desperation; ongoing raises and governance drama = sub-penny trap after the pop. Short the fade before the next offering!

**My take, first principles (real bio signal vs. listing cancer)**  
Pipeline and funding momentum could juice short-term volatility on positive reads, but leadership shakeups, dilution history, and microcap risks scream avoid beyond a quick scalp. Narrative lottery with moonshot odds but graveyard probability. Scalp the spunk? **$0.07–1.80** range, **$0.35C** bio pump—**P$0.07** dilution fade.

### 3) GCTK (GlucoTrack, Inc.): “1-for-15 Glucose Stiffy vs. Implantable CBGM & Nasdaq Bid-Price Panic”

**Why it’s loud**  
1-for-15 reverse split effective with open on August 31, 2026 (after filing/effective August 28). Healthcare tech/biopharma hybrid (Lōkahi Therapeutics platform) focused on implantable continuous blood glucose monitoring, patents, clinical manufacturing, and recent business combination. Stockholder-approved authority for up to 1-for-30 aggregate splits; explicit Nasdaq compliance goal.[[6]](https://www.sec.gov/Archives/edgar/data/1506983/000149315226040332/ex99-1.htm)[[7]](https://www.sec.gov/Archives/edgar/data/1506983/000149315226040653/0001493152-26-040653.txt)

**Bull case (compliance rocket + glucose boner)**  
15x ratio + “diabetes tech + pipeline tailwinds” = $1–3+ rip on the tightened float. Ride the health-tech wave, degens—shrunken float = huge percentage moves on any trial or partnership news!

**Bear case (dilution gangbang & sector limp dick)**  
Modest-but-repeat ratio on a compliance-chasing player with cash pressures and prior splits screams pure desperation; equity needs = sub-penny graveyard after the initial pop. Short the fade before the next treasury dump!

**My take, first principles (real tech signal vs. listing cancer)**  
Genuine patent/clinical progress could spark short-term narrative pops, but repeated compliance fights, dilution risks, and microcap volatility scream high-risk lottery ticket. Narrative lottery with moonshot odds but graveyard probability. Scalp the spunk? **$0.09–2.00** range, **$0.38C** glucose pump—**P$0.09** dilution fade.

**Tape-Side Tactics (CHGA AI Agents, VBIO Bio Bombs & GCTK Glucose Goblins – August 29 Edition)**  
- **CHGA**: **$0.08–2.20** stiffy; **$0.40C** AI pump, **P$0.08** fade.  
- **VBIO**: **$0.07–1.80** stiffy; **$0.35C** bio pump, **P$0.07** fade.  
- **GCTK**: **$0.09–2.00** stiffy; **$0.38C** glucose pump, **P$0.09** fade.  

MVLS pressure paused but reverse-split addiction still tightening the noose amid crude cock-ups and micro-madness. Balls-deep DYOR, NFA, degens duck the dilutions!

**Sources** (for tracking every claim above):  
- Reverse splits & reactions: GlobeNewswire, SEC filings, StockTitan, TipRanks, Yahoo Finance (CHGA, VBIO, GCTK announcements, Aug 27–28 2026 data).[[1]](https://www.globenewswire.com/news-release/2026/08/27/3352004/0/en/change-agents-announces-1-for-20-reverse-stock-split.html?pdf=1)[[4]](https://www.sec.gov/Archives/edgar/data/1787740/000168316826006742/valion_ex9901.htm)[[6]](https://www.sec.gov/Archives/edgar/data/1506983/000149315226040332/ex99-1.htm)  
- Company details & announcements: Company press releases, Nasdaq notices, and 8-K filings via the above.  
- Broader microcap/premarket context & volatility: Yahoo Finance, TipRanks, recent market data.
